Skip to main content
SpringerLink
Log in

The Multidisciplinary Approach to Breast Cancer Management

  • Chapter
  • First Online:
Breast & Gynecological Diseases

  • 1113 Accesses

Abstract

The goal of multidisciplinary breast cancer treatment is to optimize therapeutic effectiveness while minimizing acute and long-term toxic effects. The treatment of breast cancer is becoming more individualized. Multidisciplinary care improves patient outcomes, increases guideline-concordant care, and should be considered standard of care for the treatment of breast cancer patients. Medical oncologists, surgical oncologists, and radiation oncologists are the core group of medical providers for the multidisciplinary treatment approach of breast cancer. Consideration of the unique aspects of the patient’s history, physical examination, and family history are prerequisites for providing superior care. This chapter describes the multidisciplinary management of ductal carcinoma in situ, early-stage breast cancer, and locally advanced breast cancer. We discuss the critical steps in formulating a multidisciplinary treatment plan, including how to choose the most appropriate surgical intervention, how to determine if adjuvant radiation therapy is warranted including eligibility for alternative methods of radiation delivery, and how to determine the appropriate sequencing strategies for systemic therapy. Finally, we describe surveillance for breast cancer patients who have completed curative therapy. Communication between all teams involved in the patient’s care and coordination of care is necessary to provide the best individualized treatment possible to breast cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

ACOSOG:

American College of Surgeons Oncology Group

ALND:

Axillary lymph node dissection

APBI:

Accelerated partial breast irradiation

ASCO:

American Society of Clinical Oncology

ASTRO:

American Society for Radiation Oncology

BCS:

Breast-conserving surgery

BCT:

Breast conservation therapy

CALGB:

Cancer and Leukemia Group B

DCIS:

Ductal carcinoma in situ

DFS:

Disease-free survival

EBCTCG:

Early Breast Cancer Trialists’ Collaborative Group

EORTC:

European Organization for Research and Treatment of Cancer

ER:

Estrogen receptor

IBCSG:

International Breast Cancer Study Group

NSABP:

National Surgical Adjuvant Breast and Bowel Project

OS:

Overall survival

PMRT:

Postmastectomy radiation therapy

RTOG:

Radiation Therapy Oncology Group

SLNB:

Sentinel lymph node biopsy

WBI:

Whole breast irradiation

References

  1. Borras JM, Albreht T, Audisio R, Briers E, Casali P, Esperou H, et al. Policy statement on multidisciplinary cancer care. Eur J Cancer. 2014;50(3):475–80.

    Article  PubMed  Google Scholar 

  2. Churilla TM, Egleston BL, Murphy CT, Sigurdson ER, Hayes SB, Goldstein LJ, et al. Patterns of multidisciplinary care in the management of non-metastatic invasive breast cancer in the United States Medicare patient. Breast Cancer Res Treat. 2016;160(1):153–62.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Corter AL, Speller B, McBain K, Wright FC, Quan ML, Kennedy E, et al. Evaluating a multidisciplinary cancer conference checklist: practice versus perceptions. J Multidiscip Healthc. 2019;12:883–91.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Kesson EM, Allardice GM, George WD, Burns HJ, Morrison DS. Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13 722 women. BMJ. 2012;344:e2718.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Taylor C, Munro AJ, Glynne-Jones R, Griffith C, Trevatt P, Richards M, et al. Multidisciplinary team working in cancer: what is the evidence? BMJ. 2010;340:c951.

    Article  PubMed  Google Scholar 

  6. Al-Hilli Z, Hieken TJ, Boughey JC. Axillary ultrasound in the management of the newly diagnosed breast cancer patient. Breast J. 2015;21(6):634–41.

    Article  PubMed  Google Scholar 

  7. National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology genetic/familial high-risk assessment: breast, ovarian, and pancreatic. Version 2019. Available at: https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf.

  8. Tuttle TM, Habermann EB, Grund EH, Morris TJ, Virnig BA. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(33):5203–9.

    Article  Google Scholar 

  9. Strach MC, Prasanna T, Kirova YM, Alran S, O’Toole S, Beith JM, et al. Optimise not compromise: the importance of a multidisciplinary breast cancer patient pathway in the era of oncoplastic and reconstructive surgery. Crit Rev Oncol Hematol. 2019;134:10–21.

    Article  PubMed  Google Scholar 

  10. Park KU, Kuerer HM, Rauch GM, Leung JWT, Sahin AA, Wei W, et al. Digital breast tomosynthesis for intraoperative margin assessment during breast-conserving surgery. Ann Surg Oncol. 2019;26(6):1720–8.

    Article  PubMed  Google Scholar 

  11. Boughey JC, Hieken TJ, Jakub JW, Degnim AC, Grant CS, Farley DR, et al. Impact of analysis of frozen-section margin on reoperation rates in women undergoing lumpectomy for breast cancer: evaluation of the National Surgical Quality Improvement Program data. Surgery. 2014;156(1):190–7.

    Article  PubMed  Google Scholar 

  12. Jacobson AF, Asad J, Boolbol SK, Osborne MP, Boachie-Adjei K, Feldman SM. Do additional shaved margins at the time of lumpectomy eliminate the need for re-excision? Am J Surg. 2008;196(4):556–8.

    Article  PubMed  Google Scholar 

  13. Lombardi A, Nigri G, Maggi S, Stanzani G, Vitale V, Vecchione A, et al. Role of frozen section in sentinel lymph node biopsy for breast cancer in the era of the ACOSOG Z0011 and IBCSG 23-10 trials. Surgeon. 2018;16(4):232–6.

    Article  PubMed  Google Scholar 

  14. McLaughlin SA, Staley AC, Vicini F, Thiruchelvam P, Hutchison NA, Mendez J, et al. Considerations for clinicians in the diagnosis, prevention, and treatment of breast cancer-related lymphedema: recommendations from a multidisciplinary expert ASBrS panel: part 1: definitions, assessments, education, and future directions. Ann Surg Oncol. 2017;24(10):2818–26.

    Article  PubMed  Google Scholar 

  15. Bergmann A, da Costa Leite Ferreira MG, de Aguiar SS, de Almeida Dias R, de Souza Abrahao K, Paltrinieri EM, et al. Physiotherapy in upper limb lymphedema after breast cancer treatment: a randomized study. Lymphology. 2014;47(2):82–91.

    CAS  PubMed  Google Scholar 

  16. Vogel VG. The NSABP study of tamoxifen and raloxifene (STAR) trial. Expert Rev Anticancer Ther. 2009;9(1):51–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Nemoto T, Vana J, Bedwani RN, Baker HW, McGregor FH, Murphy GP. Management and survival of female breast cancer: results of a national survey by the American College of Surgeons. Cancer. 1980;45(12):2917–24.

    Article  CAS  PubMed  Google Scholar 

  18. American Cancer Society. Breast cancer facts and figures 2017–2018. Available at https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2017-2018.pdf.

  19. Page D, RL, SP, et al. The natural history of ductal carcinoma in situ of the breast. In: Silverstein MJ, Recht A, Lagios MD, jtans. Ductal carcinoma in situ of the breast. 2. Philiadelphia: Lippincott Williams,& Wilkins; 2002.

    Google Scholar 

  20. Sanders ME, Schuyler PA, Dupont WD, Page DL. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer. 2005;103(12):2481–4.

    Article  PubMed  Google Scholar 

  21. Rosen PP, Senie R, Schottenfeld D, Ashikari R. Noninvasive breast carcinoma: frequency of unsuspected invasion and implications for treatment. Ann Surg. 1979;189(3):377–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Blichert-Toft M, Nielsen M, Düring M, Møller S, Rank F, Overgaard M, et al. Long-term results of breast conserving surgery vs. mastectomy for early stage invasive breast cancer: 20-year follow-up of the Danish randomized DBCG-82TM protocol. Acta Oncol. 2008;47(4):672–81.

    Article  PubMed  Google Scholar 

  23. Fisher B, Redmond C, Poisson R, Margolese R, Wolmark N, Wickerham L, et al. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med. 1989;320(13):822–8.

    Article  CAS  PubMed  Google Scholar 

  24. Jacobson JA, Danforth DN, Cowan KH, d’Angelo T, Steinberg SM, Pierce L, et al. Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. N Engl J Med. 1995;332(14):907–11.

    Article  CAS  PubMed  Google Scholar 

  25. Sarrazin D, Lê MG, Arriagada R, Contesso G, Fontaine F, Spielmann M, et al. Ten-year results of a randomized trial comparing a conservative treatment to mastectomy in early breast cancer. Radiother Oncol. 1989;14(3):177–84.

    Article  CAS  PubMed  Google Scholar 

  26. van Dongen JA, Bartelink H, Fentiman IS, Lerut T, Mignolet F, Olthuis G, et al. Randomized clinical trial to assess the value of breast-conserving therapy in stage I and II breast cancer, EORTC 10801 trial. J Natl Cancer Inst Monogr. 1992;11:15–8.

    Google Scholar 

  27. Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347(16):1227–32.

    Article  PubMed  Google Scholar 

  28. Fisher B, Bauer M, Margolese R, Poisson R, Pilch Y, Redmond C, et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med. 1985;312(11):665–73.

    Article  CAS  PubMed  Google Scholar 

  29. Fisher B, Dignam J, Wolmark N, Mamounas E, Costantino J, Poller W, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol Off J Am Soc Clin Oncol. 1998;16(2):441–52.

    Article  CAS  Google Scholar 

  30. Bijker N, Meijnen P, Peterse JL, Bogaerts J, Van Hoorebeeck I, Julien JP, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24(21):3381–7.

    Article  Google Scholar 

  31. Emdin SO, Granstrand B, Ringberg A, Sandelin K, Arnesson LG, Nordgren H, et al. SweDCIS: radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening. Acta Oncol. 2006;45(5):536–43.

    Article  PubMed  Google Scholar 

  32. Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet. 2003;362(9378):95–102.

    Article  PubMed  Google Scholar 

  33. Julien JP, Bijker N, Fentiman IS, Peterse JL, Delledonne V, Rouanet P, et al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet. 2000;355(9203):528–33.

    Article  CAS  PubMed  Google Scholar 

  34. Silverstein MJ, Lagios MD, Groshen S, Waisman JR, Lewinsky BS, Martino S, et al. The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med. 1999;340(19):1455–61.

    Article  CAS  PubMed  Google Scholar 

  35. McCormick B, Winter K, Hudis C, Kuerer HM, Rakovitch E, Smith BL, et al. RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(7):709–15.

    Article  CAS  Google Scholar 

  36. Hughes LL, Wang M, Page DL, Gray R, Solin LJ, Davidson NE, et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(32):5319–24.

    Article  Google Scholar 

  37. Comparison of operative to monitoring and endocrine therapy (COMET) trial for low risk DCIS (COMET). 2016. Available from: https://clinicaltrials.gov/ct2/show/NCT02926911?cond=DCIS+comet&draw=2&rank=1.

  38. Elshof LE, Tryfonidis K, Slaets L, van Leeuwen-Stok AE, Skinner VP, Dif N, et al. Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ – the LORD study. Eur J Cancer. 2015;51(12):1497–510.

    Article  PubMed  Google Scholar 

  39. Hwang ES, Hyslop T, Lynch T, Frank E, Pinto D, Basila D, et al. The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS). BMJ Open. 2019;9(3):e026797.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Hunt KK, Meric-Bernstam F. Surgical options for breast cancer. In: Hunt KK, Robb GL, Strom EA, Ueno NT, editors. Breast cancer, M.D. Anderson cancer care series. 2nd ed. New York: Springer; 2008. https://doi.org/10.1007/978-0-387-34952-7_7.

  41. Jakub JW, Murphy BL, Gonzalez AB, Conners AL, Henrichsen TL, Maimone S, et al. A validated nomogram to predict upstaging of ductal carcinoma in situ to invasive disease. Ann Surg Oncol. 2017;24(10):2915–24.

    Article  PubMed  Google Scholar 

  42. Brunnert K. Surgery of the breast: principles and art. In: S S, jtan. Philadelphia: Lippincott-Raven; 1998.

    Google Scholar 

  43. Morrow M, Van Zee KJ, Solin LJ, Houssami N, Chavez-MacGregor M, Harris JR, et al. Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34(33):4040–6.

    Article  Google Scholar 

  44. Kuerer HM, Smith BD, Chavez-MacGregor M, Albarracin C, Barcenas CH, Santiago L, et al. DCIS Margins and breast conservation: MD Anderson Cancer Center multidisciplinary practice guidelines and outcomes. J Cancer. 2017;8(14):2653–62.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Tadros AB, Smith BD, Shen Y, Lin H, Krishnamurthy S, Lucci A, et al. Ductal carcinoma in situ and margins <2 mm: contemporary outcomes with breast conservation. Ann Surg. 2019;269(1):150–7.

    Article  PubMed  Google Scholar 

  46. Smith BD, Arthur DW, Buchholz TA, Haffty BG, Hahn CA, Hardenbergh PH, et al. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). J Am Coll Surg. 2009;209(2):269–77.

    Article  PubMed  Google Scholar 

  47. Vicini FA, Cecchini RS, White JR, Arthur DW, Julian TB, Rabinovitch RA, et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet. 2019;394(10215):2155–64.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999;353(9169):1993–2000.

    Article  CAS  PubMed  Google Scholar 

  49. Allred DC, Anderson SJ, Paik S, Wickerham DL, Nagtegaal ID, Swain SM, et al. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(12):1268–73.

    Article  CAS  Google Scholar 

  50. Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002;347(8):567–75.

    Article  PubMed  Google Scholar 

  51. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220(3):391–8; discussion 8–401.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Giuliano AE, Dale PS, Turner RR, Morton DL, Evans SW, Krasne DL. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg. 1995;222(3):394–9; discussion 9–401.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Ashikaga T, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007;8(10):881–8.

    Article  CAS  PubMed  Google Scholar 

  54. Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349(6):546–53.

    Article  PubMed  Google Scholar 

  55. Veronesi U, Viale G, Paganelli G, Zurrida S, Luini A, Galimberti V, et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg. 2010;251(4):595–600.

    Article  PubMed  Google Scholar 

  56. Ashikaga T, Krag DN, Land SR, Julian TB, Anderson SJ, Brown AM, et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol. 2010;102(2):111–8.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017;318(10):918–26.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Lucci A, McCall LM, Beitsch PD, Whitworth PW, Reintgen DS, Blumencranz PW, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(24):3657–63.

    Article  Google Scholar 

  60. Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14(4):297–305.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Boughey JC, Ballman KV, Le-Petross HT, McCall LM, Mittendorf EA, Ahrendt GM, et al. Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0–T4, N1–N2) who receive neoadjuvant chemotherapy: results from ACOSOG Z1071 (Alliance). Ann Surg. 2016;263(4):802–7.

    Article  PubMed  Google Scholar 

  62. Caudle AS, Yang WT, Krishnamurthy S, Mittendorf EA, Black DM, Gilcrease MZ, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34(10):1072–8.

    Article  CAS  Google Scholar 

  63. Caudle AS, Hunt KK, Kuerer HM, Meric-Bernstam F, Lucci A, Bedrosian I, et al. Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 study: a practice-changing trial. Ann Surg Oncol. 2011;18(9):2407–12.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Mittendorf EA, Hunt KK, Boughey JC, Bassett R, Degnim AC, Harrell R, et al. Incorporation of sentinel lymph node metastasis size into a nomogram predicting nonsentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node. Ann Surg. 2012;255(1):109–15.

    Article  PubMed  Google Scholar 

  65. Srour MK, Kim S, Amersi F, Giuliano AE, Chung A. Comparison of wire localization, radioactive seed, and Savi scout(®) radar for management of surgical breast disease. Breast J. 2020;26(3):406–13.

    Article  PubMed  Google Scholar 

  66. Moran MS, Schnitt SJ, Giuliano AE, Harris JR, Khan SA, Horton J, et al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. J Ann Soc Clin Oncol. 2014;21:704–16.

    Google Scholar 

  67. Reyes F, Noelck M, Valentino C, Grasso-Lebeau L, Lang J. Complications of methylene blue dye in breast surgery: case reports and review of the literature. J Cancer. 2010;2:20–5.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366(9503):2087–106.

    Article  CAS  PubMed  Google Scholar 

  69. Fyles AW, McCready DR, Manchul LA, Trudeau ME, Merante P, Pintilie M, et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med. 2004;351(10):963–70.

    Article  CAS  PubMed  Google Scholar 

  70. Hughes KS, Schnaper LA, Berry D, Cirrincione C, McCormick B, Shank B, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004;351(10):971–7.

    Article  CAS  PubMed  Google Scholar 

  71. Moreno AC, Shaitelman SF, Buchholz TA. A clinical perspective on regional nodal irradiation for breast cancer. Breast. 2017;34(Suppl 1):S85–90.

    Article  PubMed  Google Scholar 

  72. Poortmans PM, Collette S, Kirkove C, Van Limbergen E, Budach V, Struikmans H, et al. Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med. 2015;373(4):317–27.

    Article  CAS  PubMed  Google Scholar 

  73. Whelan TJ, Olivotto IA, Parulekar WR, Ackerman I, Chua BH, Nabid A, et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med. 2015;373(4):307–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol Off J Am Soc Clin Oncol. 1997;15(7):2483–93.

    Article  CAS  Google Scholar 

  75. National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology breast cancer. Version 5.2020. Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.

  76. Sparano JA, Gray RJ, Ravdin PM, Makower DF, Pritchard KI, Albain KS, et al. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N Engl J Med. 2019;380(25):2395–405.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014;371(2):107–18.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  78. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817–26.

    Article  CAS  PubMed  Google Scholar 

  79. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24(23):3726–34.

    Article  CAS  Google Scholar 

  80. Chen AM, Meric-Bernstam F, Hunt KK, Thames HD, Oswald MJ, Outlaw ED, et al. Breast conservation after neoadjuvant chemotherapy: the MD Anderson Cancer Center experience. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22(12):2303–12.

    Article  Google Scholar 

  81. Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med. 1997;337(14):949–55.

    Article  CAS  PubMed  Google Scholar 

  82. Overgaard M, Jensen MB, Overgaard J, Hansen PS, Rose C, Andersson M, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet. 1999;353(9165):1641–8.

    Article  CAS  PubMed  Google Scholar 

  83. Ragaz J, Olivotto IA, Spinelli JJ, Phillips N, Jackson SM, Wilson KS, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst. 2005;97(2):116–26.

    Article  PubMed  Google Scholar 

  84. Katz A, Strom EA, Buchholz TA, Thames HD, Smith CD, Jhingran A, et al. Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation. J Clin Oncol Off J Am Soc Clin Oncol. 2000;18(15):2817–27.

    Article  CAS  Google Scholar 

  85. Katz A, Strom EA, Buchholz TA, Theriault R, Singletary SE, McNeese MD. The influence of pathologic tumor characteristics on locoregional recurrence rates following mastectomy. Int J Radiat Oncol Biol Phys. 2001;50(3):735–42.

    Article  CAS  PubMed  Google Scholar 

  86. Buchholz TA, Tucker SL, Masullo L, Kuerer HM, Erwin J, Salas J, et al. Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. J Clin Oncol Off J Am Soc Clin Oncol. 2002;20(1):17–23.

    Article  CAS  Google Scholar 

  87. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol. 1999;17(2):460–9.

    Article  CAS  Google Scholar 

  88. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–717.

    Article  CAS  Google Scholar 

  89. Fisher B, Jeong JH, Bryant J, Anderson S, Dignam J, Fisher ER, et al. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet. 2004;364(9437):858–68.

    Article  CAS  PubMed  Google Scholar 

  90. Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(23):3784–96.

    Article  Google Scholar 

  91. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.

    Article  PubMed  Google Scholar 

  92. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators. JAMA. 1994;271(20):1587–92.

    Google Scholar 

  93. Rosselli Del Turco M, Palli D, Cariddi A, Ciatto S, Pacini P, Distante V. Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up. JAMA. 1994;271(20):1593–7.

    Article  CAS  PubMed  Google Scholar 

  94. Khatcheressian JL, Hurley P, Bantug E, Esserman LJ, Grunfeld E, Halberg F, et al. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(7):961–5.

    Article  CAS  Google Scholar 

  95. Margenthaler JA, Allam E, Chen L, Virgo KS, Kulkarni UM, Patel AP, et al. Surveillance of patients with breast cancer after curative-intent primary treatment: current practice patterns. J Oncol Pract. 2012;8(2):79–83.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Brittany L. Murphy, Kelly K. Hunt & Sarah M. DeSnyder

Authors
  1. Brittany L. Murphy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kelly K. Hunt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sarah M. DeSnyder
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Brittany L. Murphy .

Editor information

Editors and Affiliations

  1. Baylor College of Medicine, Houston, TX, USA

    Mahesh K. Shetty

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Murphy, B.L., Hunt, K.K., DeSnyder, S.M. (2021). The Multidisciplinary Approach to Breast Cancer Management. In: Shetty, M.K. (eds) Breast & Gynecological Diseases. Springer, Cham. https://doi.org/10.1007/978-3-030-69476-0_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-69476-0_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-69475-3

  • Online ISBN: 978-3-030-69476-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation